Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANS: Tesofensine in advanced Parkinson's disease
NCT00148512Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2003
- Primary completion
- Feb 2005
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of tesofensine in Parkinson's disease (PD) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Unified Parkinson Disease Rating Scale Parts II and III Total Score at 14 weeks and Off time during waking hours at 14 weeks. Started Mar 2003; status: completed.
02
Drugs
tesofensine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00148512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00148512.